Compare Amphastar Pharmaceuticals Inc (AMPH) vs Conagra Brands Inc (CAG) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs Conagra Brands Inc — how do they compare? Amphastar Pharmaceuticals Inc trades at $18.72 (market cap $826.08M), while Conagra Brands Inc trades at $13.89 (market cap $6.62B). The key difference: Conagra Brands Inc is far larger — about 8× Amphastar Pharmaceuticals Inc's market cap, and Conagra Brands Inc pays a 10.12% dividend while Amphastar Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMPH | CAG | |
|---|---|---|
Market Cap | $826.08M | $6.62B |
Sector | Health | Consumer Staples |
52-Week High | $30.81 | $20.02 |
52-Week Low | $16.87 | $12.58 |
Enterprise Value | $1.22B | $13.89B |
Dividend Yield | — | 10.12% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.
The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.
Conagra Brands (CAG) trades at $13.83, up 3.52% today but remains near its 52-week lows with a bearish technical outlook. The stock shows mixed fundamentals with a negative net income margin of -0.39% despite recent revenue stabilization around $11.6B. Analyst sentiment is cautious with 62.5% hold ratings, while recent news highlights concerns about dividend sustainability given the company's 10%+ yield and elevated debt levels.
CAG presents a high-risk opportunity with its deeply discounted valuation (P/E 10.06, P/B 0.81) and substantial dividend yield, but faces significant headwinds including declining earnings, high leverage, and competitive pressures in the consumer staples sector. The upcoming Q2 2026 earnings report on July 15 will be critical for confirming operational turnaround prospects.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About Conagra Brands Inc
Conagra Brands is a packaged food company that operates predominantly in the United States (over 90% of revenue and profits). It has a significant presence in the freezer aisle, with brands such as Marie Callender's, Healthy Choice, Banquet, and Birds Eye. Other popular brands include Duncan Hines, Hunt's, Slim Jim, Vlasic, Orville Redenbacher's, Reddi-wip, Wish-Bone, and Chef Boyardee. While the majority of revenue is sold into the U.S. retail channel, 9% of fiscal 2022 sales were to the food-service channel, down from 11% in fiscal 2019 due to the pandemic.
Read more on CAG →
